This NE 547 Final Exam 2026/2027 study document provides 150+ exam-focused questions and answers across 53 pages, covering major psychiatric and neurocognitive topics including Major Depressive Disorder (MDD), persistent depressive disorder, delirium, dementia and neurocognitive disorders, personality disorders, substance use disorders, bipolar disorders, psychiatric screening tools, and psychopharmacology. The document identifies the course code as NE 547 and the academic year as 2026/2027, but it does not state a university or institution; therefore, the university is accurately identified as Not Specified rather than assigning an unsupported affiliation. FINAL NE 547 2026
The first major section provides detailed review of Major Depressive Disorder and depressive disorders. Topics include diagnostic characteristics of MDD, depressive symptoms, neurovegetative and reversed neurovegetative symptoms, mild/moderate/severe presentations, and specifiers such as psychotic features, mixed features, atypical features, peripartum onset, anxious distress, seasonal pattern and melancholic features. The material also addresses persistent depressive disorder/dysthymia, substance- or medication-associated depressive symptoms, medical conditions associated with depression, electroconvulsive therapy (ECT), and depression assessment across children, adolescents and older adults. Screening instruments discussed include the Children's Depression Inventory, Children's Depression Rating Scale and Geriatric Depression Scale. FINAL NE 547 2026
A substantial portion covers delirium, dementia and neurocognitive disorders. Students review hyperactive, hypoactive and mixed delirium; risk factors and diagnostic workup; cognitive domains including executive function, complex attention, learning and memory, language, perceptual-motor function and social cognition; and distinctions between mild and major neurocognitive disorders. Dementia content includes Alzheimer disease, vascular dementia, Lewy body disease and frontotemporal dementia, along with characteristic clinical presentations, imaging and laboratory workups, differential diagnoses and cognitive screening with the Mini-Cog and MoCA. FINAL NE 547 2026
The pharmacology component reviews cholinesterase inhibitors such as donepezil, rivastigmine and galantamine, as well as memantine and anti-amyloid treatment discussed in the source material. Students also encounter medication adverse effects, contraindications and nonpharmacological interventions for dementia, alongside caregiver education involving wandering, agitation, nutrition, sleep disturbances, communication, caregiver support and end-of-life planning. FINAL NE 547 2026 For external clinical context, current evidence-based dementia resources can be found through the National Institute on Aging and the Alzheimer's Association. These are supplementary references and are not presented as the original sources of the uploaded notes.
The document then provides an extensive examination of personality disorders across Clusters A, B and C. Cluster A content includes paranoid, schizoid and schizotypal personality disorders; Cluster B includes antisocial, borderline, histrionic and narcissistic personality disorders; and Cluster C covers dependent, avoidant and obsessive-compulsive personality disorders. Questions address characteristic behavioral patterns, differential features, psychotherapy and symptom-focused pharmacological approaches. Screening and assessment material also includes the McLean Screening Instrument for borderline personality disorder. FINAL NE 547 2026
Another major section focuses on substance use disorders, intoxication, withdrawal and treatment. It covers alcohol, cannabis, opioids, sedatives/hypnotics/anxiolytics, benzodiazepines, barbiturates, stimulants, cocaine, amphetamines and hallucinogens. Alcohol-related material includes intoxication and withdrawal, delirium tremens, Wernicke encephalopathy, CIWA assessment, CAGE screening, intervention, detoxification and rehabilitation, plus medications such as acamprosate, disulfiram and naltrexone. The document additionally reviews SBIRT, DAST-10, opioid intoxication and withdrawal, naloxone, methadone, buprenorphine, stimulant intoxication and withdrawal, hallucinogen intoxication, and the stages of behavioral change. FINAL NE 547 2026 Students wanting current evidence-based substance-use guidance can cross-reference the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA).
The final section concentrates on Bipolar I, Bipolar II and cyclothymia, including manic and hypomanic presentations, differential diagnoses, the Mood Disorder Questionnaire, Bipolar Spectrum Diagnostic Scale and treatment approaches discussed in the document. Pharmacology review encompasses lithium, valproate/divalproex, lamotrigine, carbamazepine and atypical antipsychotics. The closing questions specifically review acute mania, bipolar depression, lamotrigine and Stevens–Johnson syndrome, lithium therapeutic levels, trough monitoring, renal and thyroid laboratory assessment and manifestations of lithium toxicity. FINAL NE 547 2026
Relevant students: This material is particularly relevant for NE 547 students, PMHNP students, psychiatric-mental health nursing students, graduate and advanced-practice nursing students, nurse practitioner students, and learners preparing for psychiatric nursing or psychopharmacology examinations. Its coverage also makes it useful for students reviewing DSM-oriented diagnostic concepts, neurocognitive disorders, personality disorders, substance-use assessment, psychiatric screening instruments and bipolar/depressive disorder pharmacotherapy.
Academic references: For verification and deeper study, students can cross-reference diagnostic concepts with the American Psychiatric Association's DSM-5-TR and current psychiatric practice resources. Substance-use topics can be supplemented with guidance from SAMHSA and NIDA, while dementia topics can be reviewed through the National Institute on Aging. These external references provide additional clinical context; they do not establish that every statement or medication recommendation in the uploaded exam document reflects current guidance.
Keywords: NE 547 Final Exam, NE 547 2026, NE 547 2027, NE 547 exam questions and answers, NE 547 study guide, psychiatric nursing final exam, PMHNP exam questions, psychopharmacology exam, Major Depressive Disorder, MDD diagnostic criteria, depression specifiers, persistent depressive disorder, dysthymia, ECT depression, geriatric depression scale, delirium nursing, neurocognitive disorders, dementia exam questions, Alzheimer disease, vascular dementia, Lewy body dementia, frontotemporal dementia, Mini Cog assessment, MoCA assessment, cholinesterase inhibitors, donepezil, rivastigmine, galantamine, memantine, personality disorders, Cluster A personality disorders, Cluster B personality disorders, Cluster C personality disorders, borderline personality disorder, antisocial personality disorder, narcissistic personality disorder, substance use disorder, alcohol withdrawal, delirium tremens, CIWA assessment, CAGE assessment, SBIRT, DAST 10, opioid use disorder, opioid withdrawal, naloxone, methadone, buprenorphine, stimulant intoxication, bipolar disorder, Bipolar I, Bipolar II, cyclothymia, acute mania treatment, lithium therapeutic level, lithium toxicity, lamotrigine, psychiatric mental health nursing, advanced practice nursing
Content preview
FINAL NE 547 2026/2027 Exam
Questions and Answers |
Already Graded A+
Give me the full diagnosis of Major Depressive Disorder or Unipolar
depression - ANSWER ✔✔The occurrence of at least ONE major
episode of major depression laating at least TWO WEEKS plus 5 or
more of the following symptoms:
Give me the 5 plus symptoms that have to be present to diagnose a
patient with depression - ANSWER ✔✔Feeling low most days,
anhedonia, substantial significant weight loss, change in appetite,
fidgeting, random movement, pacing
decreased energy
sense of guilt or WORTHLESSNESS
,lack of ability to focus/make decisions
repeated thoughts of suicide
Patients may describe their MDD symptoms such as: feeling hopeless,
feeling blue, reduced difficulty finishing tasks, less motivation to start
projects, agonizing emotional pain. Physically they may have
psychmotor retardation( no or little spontaneous movement), decreased
rate/volume of speech, single worded responses. Psychomotor agitation
(hang wringing, hair pulling, pacing, fidgeting) - ANSWER ✔✔
Name some neurovégétative sx of depression - ANSWER
✔✔fatigue, low energy, inattention, insomnia, early morning awakenings,
low libido, menstrual abnormalities, depression worse in the AM,
What are REVERSED neurovegatative sx? - ANSWER
✔✔INCREASED appetite
weight gain
Some other sx of depression may be: non delusional rumination of loss,
guilt, failure suicide and death. Negative views of themselves
Cognitively they can have the inability to concentrate & memory
difficulties - ANSWER ✔✔
,Tell me about the SEVERITIES of MDD. - ANSWER ✔✔Mild-
intensity of sx are manageable w/ minimal impairment functioning. The
pt has a few sx beyond required for diagnosis
Mod-The # of sx, intensity & impairment of functioning is between
mild/severe
Severe-Sx are unmanageable, distressing & they interfere with
functioning & BEYOND what is required for diagnosis
Lets review Specifiers of MDD OR UNIPOLAR depression -
ANSWER ✔✔
This specifier consists of delusions & hallucinations or other psychotic sx
present. It also has a low prognosis - ANSWER ✔✔MDD with
psychotic features
This specifier consists of 3+ manic/hypomanic sx during the depressive
episode (OCCURING ALL AT THE SAMEEE TIME NOT ONE AFTER
THE OTHER). If this occurs independently they you need to diagnose
the patient with bipolar disorder - ANSWER ✔✔MDD w/ mixed
features
COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
COPYRIGHT©PERALSARAHROSA 2026/2027. YEAR PUBLISHED PRIVACY
COMPANY REGISTRATION STATEMENT.
NUMBER: ALL RIGHTS
619652435. RESERVED
TERMS OF USE.
2026. PRIVACY STATEMENT. ALL RIGHTS RESERVED
, This MDD specifier will have some atypical sx such as reverse
neurovegatative sx : OVEREAT, OVERSLEEP. Some people will have a
comorbid anxiety, substance abuse, somatic disorder, hyposomnia,
leaden paralysis, rejection sensitivity) Usually its a younger onset -
ANSWER ✔✔MDD with atypical features
This specifier occurs during pregnancy & or up to 4 weeks post partum -
ANSWER ✔✔Peripartum onset MDD
This MDD specifier will have 2+ symptoms of anxiety. It HAS TO BE
PRESENT FOR THIS DX (restlessness, worry, fear of losing control) -
ANSWER ✔✔MDD with anxious distress
This MDD specifier usually occurs during a specific season like Winter.
These patients usually do well with light therapy for treatment -
ANSWER ✔✔MDD seasonal pattern or seasonal depression
This MDD specifier has sx of SEVERE ANHEDONIA, early morning
awakenings, weight loss, PROFOUND FEELINGS OF guilt over trivial
events, psychomotor disturbance. This is usually characterized by
autonomic nervous system changes and endocrine functions
(anorexia/weight loss). Pts have to have 3+ of above symptoms to be
considered this specifier - ANSWER ✔✔MDD with Melancholic
features